February 2017

New Product - Epclusa

Epclusa (sofosbuvir/velpatasvir) contains sofosbuvir, a nucleotide inhibitor of HCV NS5B RNA dependent RNA polymerase and velpatasvir, an HCV NS5A inhibitor. HCV NS5B RNA dependent RNA polymerase is essential for viral replication, and the HCV NS5A protein is essential for both RNA replication and the assembly of HCV virions. Epclusa is indicated for the treatment of chronic hepatitis C virus (HCV) infection (genotype 1, 2, 3, 4, 5 or 6) in adults. Epclusa is a fixed dose combination of sofosbuvir and velpatasvir. Epclusa should not be administered concurrently with other medicinal products containing any of the same active components. Epclusa tablets contain 100 mg velapatasvir and 400 mg sofosbuvir in bottles of 28’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au